| Overview |
| bsm-54043R |
| CD39 (3G4) Monoclonal Antibody |
| WB, IHC-P |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Human CD39 aa 300-450 |
| Monoclonal |
| 3G4 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
| Store for 1 year at -20C from date of shipment. Store for 1 year at -20C from date of shipment. |
| Target |
| 953 |
| P49961 |
| Ectonucleoside triphosphate diphosphohydrolase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen, NTPDase 1, Ecto-ATPDase 1, Ecto-ATPase 1, CD39, ENTPD1 |
| CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
Powered by Bioz